50 / 116
0
10
20
30
40
50
60
70
80
90
100
0 4 8 12 16 20 24 28 32 36 40 44
Progression-Free Survival, %
COMBO450
VEM
Censored patients
Median PFS in months (95% CI)
COMBO450
VEM
14.9 (11.0–20.2)
7.3 (5.6–7.9)
HR (95% CI), 0.51 (0.39–0.67)
Nominal 2-sided
P
<0.0001
Reinhard Dummer
Abstract 9504. Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus
binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma
R Dummer